The Montreal Cognitive Assessment (MoCA) is a 30-point cognitive screening test in which a score of 26 or higher is considered normal. It is reliable for flagging pronounced cognitive impairment, but not on its own: it meets only 3 of the 5 Alzheimer's Association recommendations for effective dementia screening, and a Cochrane review found that over 40% of people without dementia scored below the cutoff.
When it comes to treating cognitive impairment, early intervention is essential for delaying the onset of Alzheimer's disease and other forms of dementia. Not only does this improve patient and caregiver quality of life, but it also reduces the cost of care: spending on Alzheimer's and other dementias surpassed $277 billion in 2018, according to an Alzheimer's Association report, one factor that makes early diagnosis of dementia essential.
The MoCA remains one of the most widely used dementia screening tools in clinical practice, but its accuracy limitations mean it is rarely enough by itself. In this article, we compare the MoCA against the Alzheimer's Association recommendations for effective dementia screening and discuss the advantages of digital alternatives for cognitive screens.
Article Highlights
The Montreal Cognitive Assessment was developed by Dr. Ziad Nasreddine in 1995 for the detection of mild cognitive impairment (MCI) in clinical practice. Since then, it has become one of the most widely used cognitive screening tools among healthcare professionals in hospitals, neurology practices, and primary care settings.
Currently available in over 30 languages, the MoCA can be completed in under 10 minutes. However, it does require a trained professional to accurately interpret results. While it cannot provide a formal diagnosis of MCI or dementia, it is often used as an initial screening tool to detect cognitive deficits.
Scoring uses that 30-point scale, and the 26-point threshold is the standard marker for normal cognition. A high score requires high functioning in multiple cognitive domains that may be impaired in dementia patients, including the following:
While the MoCA has been used to accurately flag signs of advanced cognitive dysfunction, it requires follow-up testing after use to determine if dementia is present and what type of dementia a patient may be exhibiting signs of.
The Montreal Cognitive Assessment can be effective for identifying signs of pronounced cognitive impairment, but it lacks specificity and may not pick up on earlier, subtler signs of MCI. A Cochrane review found that while the MoCA was able to correctly identify over 94% of people with dementia, it also recorded a high number of false positives. In fact, over 40% of people without dementia scored under 26 points and would have been falsely flagged for dementia if their provider had used the MoCA alone.
These limitations may be related to the MoCA's susceptibility to:
When we compare the MoCA to the Alzheimer's Association's recommendations, the assessment meets only 3 out of 5 of the organization's criteria for an effective cognitive screening tool.
While the MoCA is commonly used in primary care settings, is correctly used as a screener for further testing, and outperforms the Mini-Mental State Examination on the criteria the Alzheimer's Association lists, the test does not meet some of the other requirements. For instance, the test:
As with any brief initial screener for cognitive decline, the Montreal Cognitive Assessment does not have the capacity to accurately diagnose dementia on its own. If a patient fails a cognitive function test, this may be an indication that further evaluation or a specialist referral is warranted.
On its own, the MoCA may not have the diagnostic capabilities or detail to give a full look at cognitive function. Initial assessments are a key step in clinical practice for flagging symptoms of cognitive dysfunction, allowing providers to confidently refer patients for further neurocognitive testing.
In an overtaxed system, avoiding unnecessary referrals saves time and money for patients and providers. That's where digital screening testing tools come in. Combining the MoCA with digital cognitive screens is a powerful way to gather the data providers need to deliver quality care.
Compared to traditional pen-and-paper screens like the MoCA, digital cognitive assessments carry several advantages:
Research suggests that evidence of dementia-related cognitive dysfunction can be detected up to 9 years in advance. Accurate digital tools can catch subtle symptoms that tools like the MoCA test may not, while also minimizing false positives, allowing for the earliest possible intervention for the right patients.
The Creyos Dementia Assessment is a scientifically validated, digital testing battery designed to support early dementia detection and ongoing monitoring in clinical practice. It simplifies screening practices while also providing objective, detailed insight into patient cognition.
Our dementia protocol includes three key components:
Brief, gamified online cognitive tasks measure cognitive domains that have been shown to be associated with dementia and affected by mild cognitive impairment. The two-task screener can be completed in under five minutes either remotely or in person and is scored instantly to determine if further testing is required.
Signs of cognitive impairment can be initially assessed using a two-task screener. The screener portion of the assessment is most similar to the MoCA and can be administered on its own or as part of a more comprehensive assessment that includes four additional cognitive tasks to provide more detailed information about cognition. These tasks assess:
By analyzing performance across multiple cognitive domains, the assessment can help clinicians distinguish normal aging patterns from MCI or dementia. This improves its diagnostic assistance compared to brief screening tools like the MoCA alone.
In addition to objective cognitive tasks, the Creyos assessment includes standardized questionnaires that capture subjective patient information. These data help clinicians put results in context or identify comorbidities that may be influencing cognitive function.
Included questionnaires assess the following:
Creyos extends beyond assessment with built-in tools that can use results as part of clear, actionable, and personalized care plans.
Key care planning features include the following:
This streamlined approach reduces administrative burden while enabling ongoing tracking of cognitive impairment over time. Creyos also supports documentation needs related to the CMS-HCC V28 Medicare Advantage risk adjustment system, allowing both your patients and practice to thrive.
Measured against recommendations from the Alzheimer's Association, here is how the MoCA and the Creyos Dementia Protocol compare across the five criteria:
| Alzheimer's Association criterion | MoCA | Creyos Dementia Protocol |
|---|---|---|
| Can be administered in under 5 minutes | No. Completed in under 10 minutes. | Yes. The two-test initial screener can be completed in under five minutes. |
| Free of educational, language, and cultural bias | No. Susceptible to ethnocultural, linguistic, and education-based bias. | Yes. Designed to reduce educational, language, and/or culture biases. |
| Validated in clinical settings | Yes. Outperforms the Mini-Mental State Examination (MMSE) on the criteria the Alzheimer's Association lists. | Yes. Scientifically validated in clinical settings and used in one of the world's largest dementia trials, and equal to or superior to the MMSE in specificity. |
| Easy to administer by non-physicians in primary care | Yes. Commonly used in primary care settings. | Yes. Easy to administer by non-physicians. |
| Functions as a screener that directs further assessment | Yes. Correctly used as a screener for further testing. | Yes. Includes both a screener and a detailed assessment to support next steps or referral to a specialist. |
Backed by hundreds of studies and large-scale research trials, plus real-world use in neurology and primary care settings, Creyos delivers scalable testing with high accuracy for modern dementia care.
As dementia prevalence continues to rise worldwide, healthcare providers need practical ways to adapt and better support patients experiencing cognitive dysfunction. Cognitive screening is evolving, and the shift away from tools like the Montreal Cognitive Assessment toward more detailed digital screening and assessment tools is a positive step forward.
By normalizing and simplifying cognitive assessment, providers can stay ahead of dementia care, benefiting patients, families, and clinical teams alike.
Reviewed by Mike Battista, Director of Science & Research at Creyos
Mike Battista specializes in brain health, cognition, and neuropsychological testing. He received his PhD in personality and measurement psychology at Western University in 2010 and has been doing fun and useful stuff in the intersection between science and technology ever since.